Tackling Europe's 'triple A' challenge: a bold ambition of EU's pharma legislation

29 September 2023

Addressing what has been dubbed the ‘triple A’ challenge of access, affordability and availability has been an objective of the European Medicines Agency (EMA) for nearly 30 years, going back to the launch of the centralized procedure in 1995.

As well as an extension of this procedure, efforts over the years since have included the launch of the European Network for Health Technology Assessment (EUnetHTA) Project, the Pharmaceutical Strategy for Europe that was adopted in 2020, and others.

These have helped to chip away at the triple A challenge, and the EMA is already implementing the Regulatory Science Strategy and European Medicines Regulatory Network Strategy to 2025.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical